No Data
No Data
No Data
No Data
No Data
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the resear
AccesswireApr 24 07:00 ET
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and dev
AccesswireApr 5 07:00 ET
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q4 2023 Earnings Conference
The following is a summary of the Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript:Financial Performance:Theralase Technologies reported a 6% YoY decrease in sales to $1.07 million
moomoo AIApr 3 13:30 ET · Conference Call
Theralase Technologies Reports FY Results
Seeking AlphaMar 27 10:52 ET
Theralase(R) Release's 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de
AccesswireMar 27 07:00 ET
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and deve
AccesswireMar 26 07:00 ET
No Data
No Data
wolfofTennessee : No. Spy to $360 then $330 then $300. Q3 rally and crash.